title: Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-β in macrophages.
abstract: Erythropoietin (EPO) is a pleiotropic cytokine originally identified for its role in erythropoiesis. In addition, in various preclinical models EPO exhibited protective activity against tissue injury. There is an urgent need for potent treatments of autoimmune driven disorders of the peripheral nervous system (PNS), such as the Guillain-Barré syndrome (GBS), a disabling autoimmune disease associated with relevant morbidity and mortality. To test the therapeutic potential of EPO in experimental autoimmune neuritis (EAN) - an animal model of human GBS--immunological and clinical effects were investigated in a preventive and a therapeutic paradigm. Treatment with EPO reduced clinical disease severity and if given therapeutically also shortened the recovery phase of EAN. Clinical findings were mirrored by decreased inflammation within the peripheral nerve, and myelin was well maintained in treated animals. In contrast, EPO increased the number of macrophages especially in later stages of the experimental disease phase. Furthermore, the anti-inflammatory cytokine transforming growth factor (TGF)-beta was upregulated in the treated cohorts. In vitro experiments revealed less proliferation of T cells in the presence of EPO and TGF-beta was moderately induced, while the secretion of other cytokines was almost not altered by EPO. Our data suggest that EPO revealed its beneficial properties by the induction of beneficial macrophages and the modulation of the immune system towards anti-inflammatory responses in the PNS. Further studies are warranted to elaborate the clinical usefulness of EPO for treating immune-mediated neuropathies in affected patients.
authors: Department of Neurology, Heinrich-Heine-University, Duesseldorf, Germany.
authors: Anne K
authors: AK
authors: Mausberg
authors: Gerd
authors: G
authors: Meyer Zu Hörste
authors: Thomas
authors: T
authors: Dehmel
authors: Mark
authors: M
authors: Stettner
authors: Helmar C
authors: HC
authors: Lehmann
authors: Kazim A
authors: KA
authors: Sheikh
authors: Bernd C
authors: BC
authors: Kieseier
mesh_terms: D000818:Animals; D016207:Cytokines; D004921:Erythropoietin / Q000494:pharmacology* / Q000627:therapeutic use; D007249:Inflammation; D008264:Macrophages / Q000378:metabolism*; D009444:Neuritis, Autoimmune, Experimental / Q000188:drug therapy*; D051381:Rats; D015533:Transcriptional Activation / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000819:agonists / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D016207:Cytokines; D016212:Transforming Growth Factor beta; D004921:Erythropoietin